Glucagon Pathway: In-Depth Analysis of Its Application Scope in Peptide Research
Abstract: The glucagon pathway is pivotal in peptide research, driving applications in metabolic disease therapeutics and drug development. Current market trends show a 12.3% CAGR for glucagon-like peptides, with key brands (Novo Nordisk, Eli Lilly) dominating GLP-1 analogs. Technical advantages include high receptor specificity and prolonged half-life via fatty acid acylation, while limitations involve stability and high production costs. Product comparisons highlight differences in purity (>98% vs. 95%), bioactivity, and regulatory certifications (FDA, GMP). Selection criteria prioritize lyophilized formulations, cold-chain logistics (2-8°C), and validated batch consistency. Industry growth is fueled by obesity and diabetes prevalence, with 45+ active clinical trials. Factory audits and ISO 9001 certificates are critical for quality assurance.